Discrimination of QOL-B scores by other indices of health status
| AIR-BX1 | AIR-BX2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean (SD) QOL-B scores at baseline for patients with baseline FEV1 | ||||||||
| QOL-B scale | <50% predicted (N=85) | ≥50 to <80% predicted (N=119) | ≥80% predicted (N=62) | p Value* | <50% predicted (N=79) | ≥50 to <80% predicted (N=133) | ≥80% predicted (N=62) | p Value* |
| Respiratory Symptoms | 53.4 (18.7) | 54.8 (19.3) | 58.5 (19.9) | 0.27 | 51.7 (17.5) | 57.6 (18.3) | 61.6 (16.7) | 0.004 |
| Physical Functioning | 44.9 (30.6) | 54.1 (28.6) | 64.8 (28.9) | < 0.001 | 35.5 (25.0) | 49.6 (29.0) | 63.8 (28.0) | <0.001 |
| Vitality | 51.2 (19.7) | 49.0 (21.9) | 50.1 (21.0) | 0.77 | 47.0 (20.1) | 49.1 (21.5) | 55.5 (21.1) | 0.050 |
| Role Functioning | 63.7 (25.1) | 62.8 (23.7) | 65.8 (26.2) | 0.74 | 54.5 (26.8) | 64.4 (25.5) | 67.9 (26.3) | 0.005 |
| Health Perceptions | 44.7 (20.8) | 45.5 (21.1) | 48.6 (22.6) | 0.52 | 40.4 (18.8) | 42.5 (21.4) | 49.1 (18.7) | 0.030 |
| Emotional Functioning | 79.0 (21.0) | 78.5 (19.9) | 77.3 (20.1) | 0.88 | 76.2 (21.1) | 77.2 (21.4) | 78.4 (19.5) | 0.82 |
| Social Functioning | 57.1 (25.4) | 50.5 (26.6) | 52.4 (28.0) | 0.22 | 53.3 (28.1) | 55.1 (27.9) | 56.6 (25.0) | 0.77 |
| Treatment Burden† | 65.0 (24.6) | 68.5 (24.4) | 63.1 (23.6) | 0.36 | 62.6 (23.5) | 67.2 (23.3) | 63.0 (24.9) | 0.34 |
| AIR-BX1 | AIR-BX2 | |||||
|---|---|---|---|---|---|---|
| Mean (SD) QOL-B scores at baseline for patients with baseline 6MWT: | ||||||
| QOL-B scale | Below median‡ (N=128) | Above median‡ (N=138) | p Value* | Below median‡ (N=138) | Above median‡ (N=136) | p Value* |
| Respiratory Symptoms | 53.6 (19.7) | 56.7 (18.8) | 0.20 | 52.8 (18.7) | 60.7 (16.5) | <0.001§ |
| Physical Functioning | 42.0 (29.7) | 64.5 (26.2) | <0.001 | 37.5 (26.4) | 59.9 (28.0) | <0.001 |
| Vitality | 46.1 (20.5) | 53.5 (20.9) | 0.004§ | 44.9 (19.2) | 55.0 (21.9) | <0.001 |
| Role Functioning | 57.9 (25.0) | 69.2 (23.2) | < 0.001 | 54.8 (26.4) | 69.7 (24.5) | <0.001 |
| Health Perceptions | 42.1 (20.7) | 49.6 (21.3) | 0.004§ | 40.2 (19.6) | 46.5 (20.5) | 0.009§ |
| Emotional Functioning | 77.5 (20.5) | 79.2 (20.0) | 0.49 | 74.3 (21.5) | 80.0 (19.9) | 0.024§ |
| Social Functioning | 52.1 (27.7) | 53.9 (25.7) | 0.58 | 53.8 (28.1) | 56.0 (26.5) | 0.52 |
| Treatment Burden¶ | 64.5 (24.3) | 67.8 (24.3) | 0.29 | 65.2 (24.7) | 64.7 (22.9) | 0.87 |
*p Value is from an ANOVA model with the FEV1% predicted or 6MWT category as a fixed effect. Note: patients were not randomised by these categories at baseline.
†Patients who were not receiving treatment for bronchiectasis were instructed to skip the Treatment Burden scale; data available for 82, 112 and 53 patients in AIR-BX1 and 73, 122 and 52 patients in AIR-BX2.
‡Median 6MWT was 427 metres (range 61–761) for AIR-BX1 and 436 metres (range 18–704) for AIR-BX2.
§The difference between responses below and above the median baseline 6MWT was statistically significant (p<0.05) but was less than the MID for that scale (table 7) and thus was not considered clinically significant.
¶Patients who were not receiving treatment for bronchiectasis were instructed to skip the Treatment Burden scale; data available for 126 and 121 patients in AIR-BX1 and 125 and 122 patients in AIR-BX2.
6MWT, 6 min walk test; MID, minimal important difference; QOL-B, Quality of Life-Bronchiectasis; ANOVA, analysis of variance.